Idexx Laboratories reports Q3 EPS $2.80, consensus $2.68

Reports Q3 revenue $976M, consensus $979.18M. “IDEXX teams continued their strong execution in Q3 as demonstrated by solid net customer gains, continued growth in our premium IDEXX VetLab instrument installed base, and nearly 700 pre-orders of IDEXX inVue Dx Cellular Analyzer, which will begin shipping later in Q4,” said CEO Jay Mazelsky. “Customers especially value IDEXX technology solutions like inVue Dx that provide meaningful clinical insights while giving time back to busy practice staff.”